AMCP Nexus: The Academy of Managed Care Pharmacy Nexus

Saira Jan, PharmD, MS, of Horizon Blue Cross Blue Shield of New Jersey, discussed the primary findings of their collaborative pilot program with Rutgers Cancer Institute of New Jersey and RWJ Barnabas Health, focusing on patient and provider experiences.

Operational forecasting for patients who are eligible for gene therapies will be crucial for addressing the accessibility and affordability challenges with these agents, especially as more gene therapies are expected to enter the market in the next few years.

Chelsee Jensen, PharmD, BCPS, of Mayo Clinic, commented on the recent FDA biosimilar approvals and what they mean for the industry's future, as well as how to ensure biosimilars are accessible to all patients.

During a session at AMCP Nexus, panelists provided a historical overview on the 340B drug discount program, highlighting the intentions of the plan and the research gaps leading to misconceptions about the program and whether it’s working to lower costs for patients.

Speakers at AMCP Nexus 2023 reviewed the major changes resulting from the Inflation Reduction Act (IRA) that impacted Medicare in 2023 and previewed the new provisions being implemented in the coming years.

Kristen Whelchel, PharmD, CSP, of Vanderbilt University Medical Center, details what services medically integrated dispensing (MID) specialty pharmacies provide.

At AMCP Nexus, Evernorth's Aimee Tharaldson, PharmD, provided an overview of which medications the FDA has approved in 2023 and what’s to come in nononcology areas over the next 5 years, including new drugs for Alzheimer disease, hemophilia, and nonalcoholic steatohepatitis (NASH).

Jeff McIntyre, MA, of the Global Liver Institute, discussed how the delayed diagnosis of nonalcoholic steatohepatitis (NASH) affects patients and how health care and managed care professionals can help expedite diagnosis and treatment.

Kimberly Westrich, MA, of Cencora, explains how US payers' views and uses of value assessment tools have evolved.

Panelists at AMCP Nexus provided an overview of the US obesity epidemic, dispelling myths about the causes of obesity, highlighting racial and economic disparities across the nation, and tackling how the managed care space can ensure accessibility to care for all patients.

Ben Urick, PharmD, PhD, of Prime Therapeutics, compares the value of medically integrated specialty pharmacies with that of mail order pharmacies.

A session at AMCP Nexus on the use of artificial intelligence (AI) and machine learning (ML) in managed care highlights some real-world examples of successful implementation of these technologies.

Jennifer Mathieu, MA, senior vice president of professional and government affairs of the Academy of Managed Care Pharmacy (AMCP), described what is in store for attendees during next week's AMCP Nexus meeting.

The annual fall meeting of AMCP Nexus 2023 will feature discussions on the evolving managed care landscape, including the impact of the Inflation Reduction Act, the specialty pharmaceutical pipeline, insight into the growing use of diabetes drugs for weight loss, and more.

Tam C. Phan, PharmD, AAHIVP, assistant professor of clinical pharmacy, USC School of Pharmacy, explains why it's important for pharmacists to learn about and advocate for their patients who are transgender or gender nonbinary.

Panelists at an Academy of Managed Care Pharmacy (AMCP) Nexus 2022 session discussed enhanced utilization management strategies to manage the rising cost of specialty drugs, while providing members with support for rare, complex conditions.

Chelsee Jensen, PharmD, senior pharmacy specialist at Mayo Clinic, talks about the importance of patient, provider, and nursing education as the US biosimilars landscape evolves.

The concluding keynote address at the Academy of Managed Care Pharmacy Nexus 2022 meeting discussed new and emerging oncology drugs in the pipeline and their potential impact on the treatment landscape as it pertains to managed care providers.

Chester "Bernie" Good, MD, MPH, senior medical director of the Center for Value Based Pharmacy Initiatives at UPMC Health Plan, talks about the evolution of value-based contracts.

Brian MacDonald, PharmD, senior director of specialty clinical strategy and innovation at Magellan Rx Management, explains how enhanced utilization management programs are implemented and can lead to cost avoidance for rare disease treatments.

Two posters presented at AMCP Nexus 2022 addressed the cost-effectiveness of guideline-recommended integrase strand transfer inhibitor–based triple therapy in people living with HIV, as well as the efficacy of adjuvant lenacapavir in treatment-naïve patients.

New and emerging medications in the specialty drug pipeline were discussed during a keynote address at AMCP Nexus 2022 by Aimee Tharaldson, PhD, senior clinical pharmacist of emerging therapeutics at Express Scripts, with biosimilars, orphan drugs, and cell and gene therapies emerging as key trends to watch.

Kelly Price, US Head of Rare Disease at HRA Pharma, argues proving the value of the prescription digital therapeutic (PDT) market may lead to better coverage of PDTs.

Kevin N. Astle, PharmD, assistant professor at University of South Florida Taneja College of Pharmacy, expands on HIV pre-exposure prophylaxis (PrEP) therapies in the pipeline discussed at the Academy of Managed Care Pharmacy Nexus fall 2022 meeting.

Two stakeholders from Avalere Health discuss the utility of patient-centric value frameworks for equitable health care delivery, as well as challenges and strategies regarding its implementation at Academy of Managed Care Pharmacy Nexus 2022.

Stakeholders at the Academy of Managed Care Pharmacy (AMCP) Nexus 2022 meeting review federal legislative and regulatory updates in managed care pharmacy and the impact that upcoming midterm elections will have on these provisions.

Bhavesh Shah, RPh, BCOP, chief pharmacy officer and director of specialty and hematology/oncology pharmacy at Boston Medical Center, goes over his session to be presented at the fall meeting of AMCP Nexus 2022.

The annual fall meeting of AMCP Nexus 2022 will feature a keynote from one of the top physician-executives in health care, the specialty pharmaceutical pipeline, and insights for managed care stakeholders in selecting and integrating cost-effective, value-based care frameworks.

The proposal to allow HHS to negotiate Medicare Part D drug prices is relatively realistic although the outcome will vary a lot drug by drug and class by class, said Melissa Andel, MPP, vice president of health policy at CommonHealth Solutions.

The benefit of real-world evidence is that it provides more data on subpopulations and diverse populations, said Christina Barrington, vice president of pharmacy programs at Priority Health.